Publicly visible European viral-vector manufacturing is concentrated among a small number of specialist suppliers, rather than every biologics CDMO. This guide separates four operating suppliers from one platform-stage developer: FinVector in Kuopio publicly describes cGMP viral-products manufacturing; the Kuopio Center for Gene and Cell Therapy publishes Fimea-authorized GMP AAV, adenovirus, and lentivirus services; 3PBIOVIAN in Turku publishes biologics, viral-vector, and plasmid-DNA scope; and IDT Biologika in Dessau-Rosslau publishes viral-vaccine, cell-and-gene-therapy, and aseptic fill-finish services. Fuse Vectors in Copenhagen is included as a cell-free AAV technology developer, not as a ready-to-contract CDMO. The directory does not publish capacity availability, prices, or a recommendation ranking. Use the public evidence here to build a technically plausible first-call shortlist, then confirm vector class, process maturity, quality status, technology transfer, and slot availability directly with each supplier.
This is a first-pass routing guide, not a supplier ranking. The first four operators publish manufacturing-relevant services; Fuse Vectors belongs on a technology watchlist until it publishes a contracting GMP offer. Every row requires programme-specific confirmation before an RFP.
Kuopio, Finland
Kuopio, Finland
Turku, Finland
Dessau-Rosslau, Germany
Copenhagen, Denmark
A useful first shortlist begins with the programme constraints: vector class and serotype, indication and clinical phase, target batch scale, whether plasmid DNA or fill-finish is needed, analytical-transfer needs, and the target regulatory geography. Then separate three different roles. An operating CDMO may accept a manufacturing enquiry; an adjacent cell-and-gene-therapy supplier may contribute tools or process support without offering vector manufacture; a platform developer may be relevant for future technology monitoring but not for an immediate campaign. This guide places FinVector, Kuopio Center for Gene and Cell Therapy, 3PBIOVIAN, and IDT Biologika in the first group based on public capability statements. It places Fuse Vectors in the third group. A public directory profile is a starting point for due diligence, not evidence of capacity, programme acceptance, or commercial terms.
Finland holds the most viral vector manufacturing operators in the directory. FinVector in Kuopio runs clinical-to-commercial viral vector manufacturing - the dedicated viral vector CDMO the directory surfaces at that scale in Europe. The Kuopio Center for Gene and Cell Therapy adds GMP AAV, adenovirus, and lentivirus CDMO services alongside ATMP clinical-stage capacity. 3PBIOVIAN in Turku provides a broader biologics CDMO service that includes viral vectors and plasmid DNA - useful for sponsors wanting one operator across biologics + viral vector + pDNA. Rokote Laboratories Finland in Kuopio runs nasal adenoviral-vector vaccine programmes at Phase 1 scope. Together, Finland is the European geography with the highest viral vector operator count the directory surfaces, and Kuopio specifically holds the highest operator count per city.
In Germany, IDT Biologika in Dessau-Rosslau is the viral vaccines + cell-and-gene-therapy + fill-finish CDMO the directory surfaces at commercial scale. Its public specialisation leans vaccines first, with viral vector capability sitting inside the cell-and-gene-therapy services scope. For sponsors planning viral vector programmes with an already-established EU biologics CDMO partner, IDT Biologika is the German option in the directory. Miltenyi Biotec in Bergisch Gladbach provides cell therapy platforms and clinical manufacturing tools adjacent to viral vector workflows; it is not a viral vector CDMO but supports gene therapy programmes as a tools and services supplier.
Fuse Vectors in Copenhagen is developing a cell-free viral vector manufacturing platform focused on AAV scalability. The directory classifies the company as a pre-GMP platform-stage biotech rather than a contracting CDMO - it is not yet operating commercial or clinical-scope viral vector services. Cell-free AAV manufacturing is a distinct technology route compared to traditional cell-based production at FinVector or IDT Biologika, and a scaling-frontier bet rather than a ready-to-contract option. For sponsors tracking European viral vector supply beyond current CDMO capacity, Fuse Vectors is the directory entry publicly working on the cell-free AAV problem. Maturity, clinical validation, and regulatory posture must be verified directly.
European viral vector CDMO demand comes from a broad clinical-stage cell and gene therapy layer. Germany hosts T-Knife (Berlin, TCR-T cell therapy), RHEACELL (Heidelberg, stromal cell therapy), Miltenyi Biotec (tools), and TolerogenixX (Heidelberg, tolerogenic dendritic cells). Sweden has Anocca (Sodertalje, TCR-T cell therapy), Elicera Therapeutics (Gothenburg, CAR-T and oncolytic viruses), Verigraft (Gothenburg, tissue engineering ATMPs), and Xintela (Lund, stem cell therapy). Norway adds Zelluna (Oslo, TCR-NK cell therapy). Poland hosts PolTREG (Gdansk, regulatory T-cell therapy) and Bioceltix (Wroclaw, veterinary cell therapy). Switzerland has Antion Biosciences (Geneva, multiplex gene silencing + allogeneic CAR-T). Lithuania has Froceth (Vilnius, adipose-derived cell therapy ATMP). Most of these operators run in-house or partner-based manufacturing; the CDMO layer serves the ones scaling beyond internal capacity.
Viral vector CDMO choice in Europe in 2026 depends on three technology axes. First, manufacturing mode: traditional cell-based production (FinVector, IDT Biologika, Kuopio Center, 3PBIOVIAN) vs. cell-free (Fuse Vectors, platform-stage). Cell-based covers all current commercial scope; cell-free is the scaling-frontier bet that has not yet reached commercial contracting. Second, vector class: AAV (FinVector, Kuopio Center, Fuse Vectors target), adenoviral (FinVector, Kuopio Center, IDT Biologika for vaccines, Rokote clinical), lentiviral (Kuopio Center). Third, scale: clinical-to-commercial (FinVector, IDT Biologika) vs. clinical (Kuopio Center, 3PBIOVIAN) vs. pre-GMP platform (Fuse Vectors). For sponsors, the practical question is which vector class + which scale + which manufacturing mode combination fits the specific programme.
Ask every prospective supplier the same operational questions: which vector classes, serotypes, and production systems it currently accepts; whether it supports process development, analytical development, GMP manufacture, fill-finish, and release testing; what quality authorization applies to the relevant site and activity; how a technology transfer is scoped; what material, assay, and comparability package is expected; and when a realistic development or manufacturing slot could open. Ask for current written capability information and quality documentation rather than relying on a directory summary. This makes comparisons fair and prevents a sponsor from mistaking a broad corporate service page for a programme-specific commitment.
Viral vector manufacturing is cold-chain-heavy and requires GDP-certified logistics for clinical and commercial shipments. The same operators that cover European biologics logistics (DHL Life Sciences & Healthcare, Kuehne+Nagel Healthcare, World Courier) serve viral vector movement across EU-internal and Nordic-to-continental lanes. Raw material supply for viral vector programmes (plasmid DNA, cell lines, reagents) pulls from the general European biologics supply chain, with 3PBIOVIAN providing in-house pDNA alongside viral vector manufacturing.
FinVector in Kuopio, Finland is the European dedicated viral vector CDMO the directory surfaces at clinical-to-commercial scale. The Kuopio Center for Gene and Cell Therapy (Kuopio) provides GMP AAV, adenovirus, and lentivirus services at clinical scale. 3PBIOVIAN in Turku adds a biologics + viral vectors + pDNA CDMO service. IDT Biologika in Dessau-Rosslau, Germany operates viral vaccines plus cell-and-gene-therapy fill-finish at commercial scale (vaccine-first specialisation). Fuse Vectors in Copenhagen is developing a cell-free AAV manufacturing platform - pre-GMP, not yet a contracting CDMO. Together, four operating CDMOs plus one platform-stage developer form the European viral vector CDMO layer the directory surfaces.
The Kuopio Center for Gene and Cell Therapy in Kuopio, Finland is the European operator in the directory with published lentivirus CDMO services alongside AAV and adenoviral. For cell therapy programmes using lentiviral vectors, Kuopio Center is the directory entry with explicit lentivirus scope.
Fuse Vectors in Copenhagen is developing a cell-free viral vector manufacturing platform focused on AAV scalability. Instead of producing AAV in living cells (the conventional route used by FinVector and others), cell-free manufacturing synthesises AAV capsids and packages them in an enzymatic reaction. It is a newer technology targeting the scaling limits of cell-based AAV production, currently at pre-GMP platform stage in the directory classification. Sponsors should verify current process-maturity status, clinical validation, and regulatory posture directly with the company before counting on it as contracting capacity.
The US has a larger viral vector CDMO layer in absolute operator count (Catalent, Lonza Houston, Thermo Fisher, Oxford Biomedica US, etc., most outside the scope of this directory). Europe is smaller but holds differentiated operators: FinVector as a clinical-to-commercial AAV / adenoviral CDMO, IDT Biologika as a vaccine-plus-viral-vector operator, Fuse Vectors as a cell-free technology route. For EU-market commercial launches, running viral vector manufacturing inside Europe removes a cross-regulatory layer and aligns with EMA-led clinical programmes.
Public capacity, queue position, pricing, and slot timing are not disclosed consistently enough to compare across operators. The directory therefore does not publish a lead-time estimate. Sponsors should make an early, programme-specific enquiry and ask each supplier for its current development and GMP scheduling assumptions. The meaningful comparison is whether a supplier can support the relevant vector class, process, quality package, and programme timeline - not a generic availability claim.
Sources: official public capability pages and regulatory or company disclosures linked from the source-backed Memel Biotech records for FinVector, Kuopio Center for Gene and Cell Therapy, 3PBIOVIAN, IDT Biologika, and Fuse Vectors. This is a capability map, not a capacity survey or procurement recommendation.
This brief is an editorial map of visible European viral vector CDMO capacity in 2026. Capacity availability, pricing, and open slots are not published by operators in a reliable way and change continuously. Sponsors should verify directly with each operator before engagement.
A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.